← Back to patent-cliff list
DN-022150
Tier C — Watch / tradeDN-022150
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KRAS G12D
Indications (approved)：Pancreatic cancer, Solid tumour
Regional status
US
-
EU
-
China
Phase III
2026-08-24
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of DN-022150?
Approved indications include: Pancreatic cancer, Solid tumour.
When does the DN-022150 patent expire?
No public expiry year is available for DN-022150 yet; this page updates once verified.
How do I get a quote for DN-022150 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29